NCT06704724 2026-03-13
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Active not recruiting
Clinical Trials
69 trialsNCT06883630 2026-03-05
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
RemeGen Co., Ltd.
Phase 1 Active not recruiting
NCT06447662 2026-02-25
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
Phase 1 Recruiting
NCT06333951 2026-02-19
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Amgen
Phase 1 Recruiting
NCT06124118 2026-01-08
NOVOCURE
University of Utah
Phase 1 Recruiting
NCT07216105 2025-12-17
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT02621398 2025-12-16
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
Rutgers, The State University of New Jersey
Phase 1 Completed
NCT03595059 2025-12-10
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
AbbVie
Phase 1 Completed
NCT03177291 2025-12-05
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04794699 2025-11-12
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
IDEAYA Biosciences
Phase 1 Recruiting
NCT05142189 2025-11-12
LuCa-MERIT-1
BioNTech SE
Phase 1 Recruiting
NCT05107674 2025-09-09
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT04778839 2025-08-06
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
First Affiliated Hospital of Zhejiang University
Phase 1 Recruiting
NCT06969612 2025-06-06
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
Peking University Cancer Hospital & Institute
Phase 1 Recruiting
NCT05136846 2025-06-04
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Recruiting
NCT06839105 2025-05-31
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Phase 1 Recruiting
NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
NCT05267470 2025-03-25
FORTITUDE-201
Amgen
Phase 1 Terminated
NCT03509012 2025-01-14
CLOVER
AstraZeneca
Phase 1 Completed
NCT02892123 2024-11-27
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
Phase 1 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT00107250 2023-08-04
AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)
Canadian Cancer Trials Group
Phase 1 Completed
NCT01783197 2023-08-04
Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
Canadian Cancer Trials Group
Phase 1 Completed
NCT03094884 2023-05-23
Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer
Fox Chase Cancer Center
Phase 1 Unknown
NCT02503358 2023-03-21
Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
OHSU Knight Cancer Institute
Phase 1 Completed
NCT03064854 2022-08-15
PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients
Novartis
Phase 1 Terminated
NCT02071862 2022-07-20
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT01454102 2021-10-12
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Bristol-Myers Squibb
Phase 1 Completed
NCT01711697 2021-06-23
An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Emory University
Phase 1 Unknown
NCT01199055 2020-07-07
CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Daiichi Sankyo
Phase 1 Completed
NCT01803282 2020-06-02
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Completed
NCT03920839 2020-04-24
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
Incyte Corporation
Phase 1 Withdrawn
NCT03780010 2019-10-28
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
Tracon Pharmaceuticals Inc.
Phase 1 Completed
NCT02944396 2019-10-23
Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
AbbVie
Phase 1 Completed
NCT02367352 2019-06-26
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
Takeda
Phase 1 Terminated
NCT00025480 2019-03-13
Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT02252796 2018-05-30
HySBst
West Virginia University
Phase 1 Terminated
NCT01486602 2018-01-19
Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT02172846 2017-12-08
Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer
Washington University School of Medicine
Phase 1 Completed
NCT01225302 2017-11-21
A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)
AbbVie
Phase 1 Completed
NCT00866528 2017-11-13
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
GlaxoSmithKline
Phase 1 Completed
NCT01702714 2016-11-04
A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease
Hoffmann-La Roche
Phase 1 Withdrawn
NCT00974584 2016-11-02
A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
Genentech, Inc.
Phase 1 Completed
NCT02083679 2016-10-25
Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer
EMD Serono
Phase 1 Terminated
NCT02033551 2016-09-27
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
AbbVie
Phase 1 Completed
NCT00702572 2016-09-22
Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer
Milton S. Hershey Medical Center
Phase 1 Terminated
NCT02728492 2016-05-03
Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
NewVac LLC
Phase 1 Completed
NCT00533585 2016-02-10
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00016315 2015-11-17
Gemcitabine, Carboplatin or Paclitaxel Plus Radiation Therapy in Treating Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
Phase 1 Completed
NCT00020007 2015-04-29
Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Completed